Ovagen
Also known as: Lys-Glu-Asp, KED, Hepato-GI Bioregulator
Ovagen (KED) is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator program targeting liver and gastrointestinal tract tissue. It is researched for hepatoprotection, GI mucosal restoration, and anti-aging effects on digestive system function.
Ovagen is a 365.34 Da research peptide. Ovagen (KED) is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator program targeting liver and gastrointestinal tract tissue. It is researched for hepatoprotection, GI mucosal restoration, and anti-aging effects on digestive system function.
Also called: Lys-Glu-Asp, KED, Hepato-GI Bioregulator
365.34
Molecular Weight
Daltons
0
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
5000-10000
Typical Dose
mcg
Overview
Ovagen is a synthetic tripeptide consisting of Lysine-Glutamic acid-Aspartic acid (KED), developed as a bioregulator for liver and gastrointestinal tract tissue. It is closely related to Livagen (KEDA) but targets both hepatic and GI mucosal tissue. The Khavinson group's research suggests Ovagen modulates gene expression in hepatocytes and GI epithelial cells, supporting mucosal barrier integrity, digestive enzyme secretion, and hepatic detoxification function. It has been studied in models of toxic hepatitis, gastric ulceration, and age-related digestive decline. Available in Russia as oral capsules, Ovagen is positioned as a broader digestive system bioregulator compared to the liver-specific Livagen.
Key Takeaways: Ovagen
- Research doses typically range from 5000 to 10000 mcg via oral capsule
- 0 benefits with strong evidence, 0 moderate, 4 preliminary
- Half-life: Minutes (typical of short peptides)
- 3 cited research studies in this guide
Mechanism of Action
Ovagen is proposed to regulate gene expression in hepatocytes and GI epithelial cells through direct peptide-DNA interaction. In liver tissue, it upregulates genes involved in Phase I/II detoxification enzymes, albumin synthesis, and antioxidant defense (SOD, glutathione peroxidase). In GI tissue, Ovagen modulates expression of mucin genes (MUC2, MUC5AC) supporting mucosal barrier integrity, tight junction protein expression, and epithelial cell turnover. The peptide may also influence local immune function in gut-associated lymphoid tissue (GALT) by modulating IgA secretion and epithelial cytokine signaling. Age-related decline in digestive function is proposed to result from altered gene expression in GI and hepatic tissue, which Ovagen aims to normalize.
Research Benefits
Ovagen at a Glance
Ovagen is proposed to regulate gene expression in hepatocytes and GI epithelial cells through direct peptide-DNA interaction.
Hepatoprotection
PreliminaryResearch shows protective effects against toxic liver injury with normalization of hepatic enzyme levels in animal models.
GI Mucosal Restoration
PreliminaryProposed restoration of GI mucosal barrier integrity, mucin production, and epithelial cell turnover in aging digestive tissue.
Digestive Function Support
PreliminaryClinical observations suggest improved digestive function markers and symptom scores in elderly patients with age-related digestive decline.
Liver and GI Gene Expression Normalization
PreliminaryProposed restoration of youthful gene expression patterns in hepatocytes and GI epithelial cells.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Oral capsule protocol | 5000–10000 mcg | Oral capsule |
| Subcutaneous protocol | 5000–10000 mcg | Subcutaneous injection |
Frequency
Once or twice daily during treatment courses
Timing
Before meals for GI applications; no strict requirement for hepatic
Cycle Length
10-30 day courses, repeated 2-3 times per year
Research Notes
- 1Available in Russia as oral supplement capsules.
- 2Broader GI+liver targeting vs. Livagen (liver-specific).
- 3Most research from Russian institutions.
- 4No serious adverse effects reported.
Reconstitution Guide
Standard Reconstitution
Vial Size
10 mg
Bacteriostatic Water
2 mL
Concentration
50 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Ovagen vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at Refrigerated (2-8°C) after reconstitution. Up to 30 days refrigerated.
Storage Temperature
Refrigerated (2-8°C) after reconstitution
Shelf Life
Up to 30 days refrigerated
Important Notes
- •Reconstitute with bacteriostatic water.
- •Small, stable tripeptide.
- •Most commonly used in oral capsule form.
Ovagen Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Ovagen Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (mild)
- !No significant adverse effects reported
- !Mild GI changes during initial use (rare)
- !Well tolerated in published research
Potential Interactions
- ⚡Compatible with other Khavinson bioregulators.
- ⚡No adverse interactions reported with standard GI medications.
- ⚡Theoretical additive hepatoprotective effects with milk thistle and other liver support agents.
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
KED peptide effects on hepatocyte gene expression
Demonstrated Ovagen modulates gene expression in hepatocyte cultures, affecting detoxification enzyme and antioxidant gene expression.
Peptide bioregulators for GI tract restoration in aging
Reviewed GI-targeting peptide bioregulators including Ovagen, showing improved mucosal barrier markers and digestive function in aged animal models.
Short peptide regulation of liver and GI tissue
thorough review of liver and GI bioregulatory peptides, including KED peptide's dual tissue targeting and proposed mechanisms.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Ovagen (KED) is a tripeptide bioregulator targeting both liver and GI tract tissue. It supports hepatoprotection, mucosal barrier integrity, and digestive function restoration.
Livagen (KEDA, 4 amino acids) is liver-specific with demonstrated chromatin decondensation. Ovagen (KED, 3 amino acids) targets both liver and GI tract more broadly. They are related but distinct peptides.
Evidence is primarily from Russian institutions at the preliminary level. Most data comes from cell culture, animal models, and clinical observations rather than controlled trials.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.